Who are ACTHAR Gel (ACTH)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Open label H.P. Acthar Gel, Acthar low dose (40 U), Tricortin 1000, Purified Cortophin Gel, 40 U, H.P. Acthar Gel, Purified Cortophin Gel 80 U.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acthar-gel-acth.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ACTHAR Gel (ACTH) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACTHAR Gel (ACTH) (ACTHAR Gel (ACTH)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACTH analog. Area: Immunology.

marketed ACTH analog Melanocortin-2 receptor (MC2R) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ACTHAR Gel (ACTH) (ACTHAR Gel (ACTH)) — University of Colorado, Denver. ACTHAR Gel is a synthetic adrenocorticotropic hormone (ACTH) that stimulates the adrenal cortex to produce and release cortisol and other corticosteroids.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ACTHAR Gel (ACTH) TARGET	ACTHAR Gel (ACTH)	University of Colorado, Denver	marketed	ACTH analog	Melanocortin-2 receptor (MC2R)
Open label H.P. Acthar Gel	Open label H.P. Acthar Gel	Fiechtner, Justus J., M.D., P.C.	marketed	Corticotropin (ACTH analog)	Melanocortin-2 receptor (MC2R)
Acthar low dose (40 U)	Acthar low dose (40 U)	NYU Langone Health	marketed	ACTH analog	Melanocortin-2 receptor (MC2R)
Tricortin 1000	Tricortin 1000	Fidia Farmaceutici s.p.a.	marketed	ACTH analog	Melanocortin-2 receptor (MC2R)
Purified Cortophin Gel, 40 U	Purified Cortophin Gel, 40 U	Massachusetts General Hospital	marketed	ACTH analog / corticotropin	Melanocortin-2 receptor (MC2R)
H.P. Acthar Gel	H.P. Acthar Gel	Fiechtner, Justus J., M.D., P.C.	marketed	Corticotropin (ACTH analog)	Melanocortin-2 receptor (MC2R)
Purified Cortophin Gel 80 U	Purified Cortophin Gel 80 U	Massachusetts General Hospital	marketed	ACTH analog / corticotropin	Melanocortin-2 receptor (MC2R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACTH analog class)

NYU Langone Health · 2 drugs in this class
Attune Health Research, Inc. · 1 drug in this class
Fidia Farmaceutici s.p.a. · 1 drug in this class
University of Colorado, Denver · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACTHAR Gel (ACTH) — Competitive Intelligence Brief. https://druglandscape.com/ci/acthar-gel-acth. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing